Biota to beef up flu drug lawsuit
Biota plans to hike up its damages claim against Europe's biggest drugmaker for failing to promote flu drug Relenza properly.
Peter Cook, chief executive of Biota Holdings Ltd, said the Melbourne-based biotech firm would file its revised claim against GlaxoSmithKline next month.
Biota started its litigation in May 2004 and is currently seeking up to $A430 million in damages.
Cook said this original claim would be increased because it failed to take into account the recent explosion in demand for flu drugs, which are being stockpiled by governments around the world in case of a pandemic that may be triggered by bird flu.
Biota claims Glaxo failed to back it properly and so lost out when demand for flu drugs soared after the H5N1 bird flu virus re-emerged in Asia in 2003.
D'oh! Another lawsuit for poor old GSK
Author of The evidence, however, is clear, the Seroxat scandal
Citizens Commission on Human Rights Award Recipient (Twice)